<DOC>
	<DOCNO>NCT01278342</DOCNO>
	<brief_summary>This study assess efficacy 8 month treatment Sandostatin® LAR® High Dose monotherapy Sandostatin® LAR® High Dose combination either growth hormone antagonist dopamine agonist control biochemical parameter ( GH insulin-like growth factor I [ IGF I ] ) acromegalic patient achieve biochemical normalization conventional regimen .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety Sandostatin LAR High Dose Combination Either With GH-receptor Antagonist Dopamine-agonist Acromegalic Patients</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Cabergoline</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<mesh_term>Dopamine Agonists</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<mesh_term>Dopamine Agents</mesh_term>
	<criteria>• Patient biochemically document active acromegaly , adequately control somatostatinanalogues conventional regimen follow : mean 1hour GH &gt; 2.5 ng/mL elevate IGF1 ( adjust age gender ) Patient reduction either mean fast GH least 50 % IGF1 least 25 % medical pretreatment level Patient currently receive somatostatinanalogues conventional regimen ( maximum register dose ) least 6 month inclusion Newly diagnose previously medically untreated acromegalic patient Concomitant treatment GHreceptor antagonist Concomitant treatment dopamineagonist Symptomatic cholelithiasis choledocolithiasis Liver transaminases ( ALT , AST ) elevate , &gt; 3 time upper normal limit ( accord local laboratory ) Previous gammaknife radiotherapy treatment acromegaly Compression optic chiasm cause visual field defect Any medical condition contraindicate Summary Product Characteristic ( SPC ) drug Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Sandostatin LAR</keyword>
	<keyword>High Dose</keyword>
	<keyword>GH-receptor antagonist</keyword>
	<keyword>combination dopamine-agonist</keyword>
	<keyword>acromegalic patient</keyword>
	<keyword>octreotide acetate</keyword>
	<keyword>Somavert</keyword>
	<keyword>Dostinex</keyword>
	<keyword>pegvisomant</keyword>
	<keyword>cabergoline</keyword>
	<keyword>adequately control</keyword>
	<keyword>active acromegaly</keyword>
</DOC>